Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma

Onkologie

Volumn 31, Issue 8-9, 2008, Pages 485-

  Kahl, Christoph ^a   Hilgendorf, Inken ^a   Freund, Mathias ^a   Casper, Jochen ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b KLINIKUM OLDENBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; FLUOROURACIL; INTERFERON; SUNITINIB;

ADULT; AGED; CANCER PATIENT; CASE REPORT; DIARRHEA; DISEASE COURSE; DRUG MECHANISM; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LETTER; METASTASIS; MUSCLE HYPERTONIA; TREATMENT RESPONSE; WEAKNESS;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 52249112271     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000142359     Document Type: Letter

References (3)

1. Mendel DB, Laird AD, Xin X, et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337.
2. Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124.
3. Blay JY, George S, Casali PG, et al.: Continuous daily dosing (CDD) study of sunitinib malate (SU) in patients (pts) with advanced GIST compares favorably with intermittent dosing. Eur J Cancer 2007;5(suppl):402, Abstr. O#7501.